UK campaign for access to treatments and support for those with spinal muscular atrophy
Pressure put on NHS by the UK medical and patient communities bore fruit last week when NHS England finally agreed to amend its Commissioning Policy for Nusinersen Expanded Access Programme so as to include all those with SMA type 1.
The Spanish government announced that Spinraza has become available to the majority of people with spinal muscular atrophy covered by the Spanish healthcare system.
If you or someone close to you are affected by spinal muscular atrophy, please help to advocate for wide access to Spinraza in the UK.
Biogen has provided the following community statement on the final results from CHERISH, a Phase 3 study of SPINRAZA.
Norway agreed to fund Spinraza
If you or someone close to you are affected by spinal muscular atrophy, please help to advocate for wide access to Spinraza in the UK. We ask you to complete a few short surveys on the SMA Support UK website.
On 25–27 January, we were at the International Scientific Congress on SMA.
TreatSMA members and their children attended a Fast Track Treatment Campaign meeting at the House of Commons.
Biogen accounces that Spinraza will be available through a Managed Access Scheme.
